Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 24, 2026, 4:15 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 865–888 of 1,656 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Growth Clear all
Completed Phase 2 Interventional Results available

M7824 Monotherapy in Locally Advanced or Metastatic Second Line (2L) Biliary Tract Cancer (Cholangiocarcinoma and Gallbladder Cancer)

NCT03833661
View directory record Official record
Conditions
Biliary Tract Cancer, Cholangiocarcinoma, Gallbladder Cancer
Interventions
M7824
Drug
Lead sponsor
EMD Serono Research & Development Institute, Inc.
Industry
Eligibility
18 Years and older
Enrollment
159 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
7
States / cities
Scottsdale, Arizona • San Francisco, California • Jacksonville, Florida + 4 more
Source: ClinicalTrials.gov public record
Updated Oct 25, 2023 · Synced Oct 24, 2026, 4:15 PM EDT
Completed Phase 2 Interventional

Safety and Preliminary Efficacy of Activated Recombinant Human Factor VII for Preventing Early Hematoma Growth in Acute Intracerebral Haemorrhage

NCT01563445
View directory record Official record
Conditions
Acquired Bleeding Disorder, Intracerebral Haemorrhage
Interventions
activated recombinant human factor VII, placebo
Drug
Lead sponsor
Novo Nordisk A/S
Industry
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2003
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jan 13, 2017 · Synced Oct 24, 2026, 4:15 PM EDT
Recruiting No phase listed Observational Accepts healthy volunteers

Natural History of Craniofacial Anomalies and Developmental Growth Variants

NCT02639312
View directory record Official record
Conditions
Prognathism, Retrognathism, Dentofacial Deformities
Interventions
Not listed
Lead sponsor
National Institute of Dental and Craniofacial Research (NIDCR)
NIH
Eligibility
2 Years to 100 Years
Enrollment
2,400 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2046
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 1, 2026 · Synced Oct 24, 2026, 4:15 PM EDT
Completed No phase listed Observational

Baby Observational and Nutritional Study

NCT01424696
View directory record Official record
Conditions
Cystic Fibrosis, Growth Failure, Exocrine Pancreatic Insufficiency
Interventions
Not listed
Lead sponsor
Seattle Children's Hospital
Other
Eligibility
Up to 3 Months
Enrollment
231 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2015
U.S. locations
28
States / cities
Birmingham, Alabama • Little Rock, Arkansas • Aurora, Colorado + 24 more
Source: ClinicalTrials.gov public record
Updated Sep 28, 2015 · Synced Oct 24, 2026, 4:15 PM EDT
Completed Phase 1 Interventional

A First-in-Human, Phase 1 Study of JAB-3312 in Adult Patients With Advanced Solid Tumors

NCT04045496
View directory record Official record
Conditions
Non-small Cell Lung Cancer, Colorectal Cancer, Pancreatic Ductal Carcinoma, Esophageal Squamous Cell Carcinoma, Head and Neck Squamous Cell Carcinoma, Breast Cancer, Other Solid Tumors
Interventions
JAB-3312
Drug
Lead sponsor
Jacobio Pharmaceuticals Co., Ltd.
Industry
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
4
States / cities
Denver, Colorado • Nashville, Tennessee • Houston, Texas + 1 more
Source: ClinicalTrials.gov public record
Updated Dec 29, 2025 · Synced Oct 24, 2026, 4:15 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Weight Patterns in the Month After Birth

NCT04025827
View directory record Official record
Conditions
Stunting, Wasting, Undernutrition, Feeding Patterns, Feeding; Difficult, Newborn, Feeding, Breast
Interventions
Dietary intake
Other
Lead sponsor
University of California, San Francisco
Other
Eligibility
Up to 24 Hours
Enrollment
741 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2021
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated May 13, 2021 · Synced Oct 24, 2026, 4:15 PM EDT
Completed Not applicable Interventional

Exclusive Human Milk Feeding in Infants With Single Ventricle Physiology

NCT02860702
View directory record Official record
Conditions
Congenital Heart Defect
Interventions
Human Milk Derived Fortifier, Human/Bovine Milk
Other
Lead sponsor
The University of Texas Health Science Center at San Antonio
Other
Eligibility
1 Day to 7 Days
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2022
U.S. locations
12
States / cities
Loma Linda, California • Los Angeles, California • Orange, California + 9 more
Source: ClinicalTrials.gov public record
Updated Sep 26, 2023 · Synced Oct 24, 2026, 4:15 PM EDT
Completed Phase 1 Interventional

Phase 1b Study of PD-0332991 in Combination With T-DM1(Trastuzumab-DM1)

NCT01976169
View directory record Official record
Conditions
Advanced Breast Cancer
Interventions
PD-0332991 and T-DM1
Drug
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
18 Years to 90 Years
Enrollment
29 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2021
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Feb 8, 2022 · Synced Oct 24, 2026, 4:15 PM EDT
Completed Phase 2 Interventional Results available

Growth Hormone and Intrahepatic Lipid Content in Patients With Nonalcoholic Fatty Liver Disease

NCT02217345
View directory record Official record
Conditions
Nonalcoholic Fatty Liver Disease (NAFLD)
Interventions
Growth hormone, Placebo
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years to 65 Years
Enrollment
131 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2021
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Nov 22, 2022 · Synced Oct 24, 2026, 4:15 PM EDT
Active, not recruiting No phase listed Observational Accepts healthy volunteers

Release Kinetics in PRF Versus GEM21S With and Without Bone Substitutes: An In Vitro Analysis

NCT04964466
View directory record Official record
Conditions
Bone Loss
Interventions
Amount of PDGF-BB in PRF preparation vs. GEM21, Amount of PDGF-BB available in PRF + bone substitutes vs. rhPDGF-BB+ bone substitutes following preparation, Release kinetics of PDGF-BB in PRF + bone substitutes vs. rhPDGF-BB + bone substitutes, Release kinetics of PDGF-BB in rhPDGF-BB + PRF + bone substitutes
Biological
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
18 Years to 99 Years
Enrollment
5 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2026
U.S. locations
1
States / cities
Birmingham, Alabama
Source: ClinicalTrials.gov public record
Updated Dec 2, 2025 · Synced Oct 24, 2026, 4:15 PM EDT
Completed Phase 1Phase 2 Interventional Results available

AZD9291 First Time In Patients Ascending Dose Study

NCT01802632
View directory record Official record
Conditions
Advanced Non Small Cell Lung Cancer, Advanced (Inoperable) Non Small Cell Lung Cancer
Interventions
AZD9291
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 130 Years
Enrollment
603 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2023
U.S. locations
7
States / cities
Aurora, Colorado • Atlanta, Georgia • Boston, Massachusetts + 3 more
Source: ClinicalTrials.gov public record
Updated Apr 20, 2026 · Synced Oct 24, 2026, 4:15 PM EDT
Completed Not applicable Interventional

Effects of Aerobic Exercise on Cognition, Mood and Fatigue Following TBI

NCT00619463
View directory record Official record
Conditions
Traumatic Brain Injury
Interventions
Exercise
Behavioral
Lead sponsor
Icahn School of Medicine at Mount Sinai
Other
Eligibility
18 Years and older
Enrollment
154 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2012
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Sep 24, 2013 · Synced Oct 24, 2026, 4:15 PM EDT
Recruiting Phase 1Phase 2 Interventional

Super-selective Intra-arterial Repeated Infusion of Cetuximab for the Treatment of Newly Diagnosed Glioblastoma

NCT02861898
View directory record Official record
Conditions
Glioblastoma, Brain Cancer, Brain Neoplasm, Brain Tumor, Brain Neoplasm, Malignant, EGFR Gene Overexpression, GBM
Interventions
Intra-arterial Cetuximab, Intra-arterial Mannitol
Drug
Lead sponsor
Northwell Health
Other
Eligibility
18 Years and older
Enrollment
33 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2029
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jun 1, 2026 · Synced Oct 24, 2026, 4:15 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Peanut Protein Supplementation to Augment Muscle Growth and Improve Markers of Muscle Quality and Health in Young Adults

NCT04707963
View directory record Official record
Conditions
Sarcopenia
Interventions
Peanut protein powder, Full body resistance training
Dietary Supplement · Behavioral
Lead sponsor
Auburn University
Other
Eligibility
18 Years to 30 Years
Enrollment
56 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021
U.S. locations
1
States / cities
Auburn, Alabama
Source: ClinicalTrials.gov public record
Updated Jun 9, 2021 · Synced Oct 24, 2026, 4:15 PM EDT
Active, not recruiting Phase 1 Interventional

Study of AC699 in Patients With Estrogen Receptor Positive/Human Epidermal Growth Factor Receptor 2 Negative (ER+/HER2-) Locally Advanced or Metastatic Breast Cancer

NCT05654532
View directory record Official record
Conditions
Breast Cancer
Interventions
AC699
Drug
Lead sponsor
Accutar Biotechnology Inc
Industry
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
9
States / cities
Denver, Colorado • Orlando, Florida • Sarasota, Florida + 6 more
Source: ClinicalTrials.gov public record
Updated Sep 30, 2025 · Synced Oct 24, 2026, 4:15 PM EDT
Completed Phase 2 Interventional Results available

Study of the Intravitreal Plasma Kallikrein Inhibitor, KVD001, in Subjects With Center-involving Diabetic Macular Edema (ciDME)

NCT03466099
View directory record Official record
Conditions
Diabetic Macular Edema
Interventions
KVD001 Injection, Sham Procedure
Drug · Other
Lead sponsor
KalVista Pharmaceuticals, Ltd.
Industry
Eligibility
18 Years and older
Enrollment
129 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
35
States / cities
Phoenix, Arizona • Tucson, Arizona • Arcadia, California + 28 more
Source: ClinicalTrials.gov public record
Updated Jan 28, 2021 · Synced Oct 24, 2026, 4:15 PM EDT
Completed No phase listed Observational

A Study to Learn About the Dangers Linked to Myelosuppression (Decreased Bone Marrow Function) in Breast Cancer Patients Treated With the Study Medicine Palbociclib (Pal Bow Sai Klib)

NCT05709158
View directory record Official record
Conditions
Breast Cancer
Interventions
Not listed
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
4,184 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jun 2, 2026 · Synced Oct 24, 2026, 4:15 PM EDT
Terminated Phase 4 Interventional Results available

Sodium Supplementation and Growth in Very Low Birth Weight Infants

NCT01795638
View directory record Official record
Conditions
Extreme Immaturity
Interventions
Sodium chloride, Placebo
Drug
Lead sponsor
Children's Hospital Medical Center, Cincinnati
Other
Eligibility
7 Days to 8 Days
Enrollment
53 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Sep 7, 2020 · Synced Oct 24, 2026, 4:15 PM EDT
Terminated Phase 2 Interventional Accepts healthy volunteers Results available

Three Month Treatment of Growth Hormone Releasing Hormone (GHRH) in the Elderly

NCT01410799
View directory record Official record
Conditions
Hormone Deficiency, Aging
Interventions
Growth Hormone Releasing Hormone (GHRH )
Drug
Lead sponsor
University of Pennsylvania
Other
Eligibility
65 Years and older
Enrollment
13 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated May 24, 2019 · Synced Oct 24, 2026, 4:15 PM EDT
Active, not recruiting Phase 2 Interventional

Study of Osimertinib With and Without Ramucirumab in Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)

NCT03909334
View directory record Official record
Conditions
Non Small Cell Lung Cancer, EGFR Gene Mutation, Advanced Cancer, Metastatic Cancer
Interventions
Osimertinib, Ramucirumab
Drug
Lead sponsor
Xiuning Le
Other
Eligibility
18 Years and older
Enrollment
160 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2027
U.S. locations
12
States / cities
Washington D.C., District of Columbia • Tampa, Florida • Chicago, Illinois + 7 more
Source: ClinicalTrials.gov public record
Updated Apr 17, 2026 · Synced Oct 24, 2026, 4:15 PM EDT
Completed Phase 2 Interventional

Growth Factor to Prevent Oral Mucositis in Patients With Hematologic Cancer

NCT00004132
View directory record Official record
Conditions
Drug/Agent Toxicity by Tissue/Organ, Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm, Oral Complications, Radiation Toxicity
Interventions
filgrastim, palifermin, cyclophosphamide, etoposide, ifosfamide, quality-of-life assessment, radiation therapy
Biological · Drug · Procedure + 1 more
Lead sponsor
Jonsson Comprehensive Cancer Center
Other
Eligibility
12 Years to 65 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2004
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Jun 26, 2013 · Synced Oct 24, 2026, 4:15 PM EDT
Completed Phase 3 Interventional Accepts healthy volunteers

Growth and Tolerance of Young Infants Fed Infant Formulas

NCT01380886
View directory record Official record
Conditions
Infant Newborn
Interventions
experimental infant formula with alternate protein source, Infant formula powder
Other
Lead sponsor
Abbott Nutrition
Industry
Eligibility
Up to 8 Days
Enrollment
209 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011
U.S. locations
12
States / cities
Norwich, Connecticut • St. Petersburg, Florida • Indianapolis, Indiana + 9 more
Source: ClinicalTrials.gov public record
Updated Feb 15, 2013 · Synced Oct 24, 2026, 4:15 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Effect of DPP4 Inhibition on Growth Hormone Secretion

NCT01701973
View directory record Official record
Conditions
Obesity
Interventions
Sitagliptin, Pegvisomant, Placebo, L-NMMA, Exendin 9-39
Drug
Lead sponsor
Vanderbilt University
Other
Eligibility
18 Years to 40 Years
Enrollment
44 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2017
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated May 29, 2018 · Synced Oct 24, 2026, 4:15 PM EDT
Completed Not applicable Interventional

Growth, Empowerment, and Mindfulness (GEM): A Mindfulness-based Intervention to Address Mental Health in Young Adults With Early Life Adversity

NCT07546799
View directory record Official record
Conditions
Anxiety, Depression
Interventions
Growth, Empowerment, and Mindfulness (GEM)
Behavioral
Lead sponsor
Brown University
Other
Eligibility
18 Years to 24 Years
Enrollment
44 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026
U.S. locations
1
States / cities
Providence, Rhode Island
Source: ClinicalTrials.gov public record
Updated Sep 9, 2026 · Synced Oct 24, 2026, 4:15 PM EDT